US EditionPublished • loading... • Updated
Novartis Misses Q1 Profit, Sales Estimates as Generics Hurt Blockbuster Entresto Sales
Entresto sales fell 42% as Novartis said generic competition and patent expiries pushed quarterly profit and revenue below analyst estimates.
- On Tuesday, April 28, 2026, Swiss drugmaker Novartis reported first-quarter core operating profit and sales below market expectations, with total net sales of $13.1 billion missing analyst expectations of $13.4 billion.
- Generic competition for Entresto in the United States caused the revenue slump, with the blockbuster heart drug's sales plummeting 46% to $1.3 billion after U.S. patent expiry.
- Growth products including Kisqali and Kesimpta performed well, rising 55% to $1.52 billion and 26% to $1.16 billion respectively, while Tasigna and Promacta/Revolade continue facing generic competition.
- Shares fell 2.5% following the earnings report as quarterly operating income declined 12% to $4.9 billion and earnings per share dropped 13% to $1.99.
- CEO Vas Narasimhan expects growth to return in the second half of this year, though the company anticipates a $4 billion revenue hit this year and notes the U.S. Most-Favoured Nation pricing policy may impact results over the next 18 months.
Insights by Ground AI
11 Articles
11 Articles
·United Kingdom
Read Full Article
Novartis (NVS) Stock Drops 2% After Q1 Revenue Miss and Entresto Sales Plunge 42%
Key Takeaways Shares of NVS declined approximately 2% during pre-market trading following a first quarter earnings disappointment Revenue totaled $13.11B, falling short of the $13.40B Wall Street projection, representing a 1% year-over-year decline Sales of Entresto plummeted 42% to $1.31B following U.S. patent loss and entry of generic alternatives Core earnings per share decreased to $1.99 from $2.28; core operating profit contracted 12% to $…
Coverage Details
Total News Sources11
Leaning Left0Leaning Right1Center3Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
C 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium
